Endocannabinoids, CB1 Receptors, and Liver Disease: Hitting More Than One Bird With the Same Stone

Gastroenterology

Volumn 134, Issue 2, 2008, Pages 622-625

  Kunos, George ^a   Gao, Bin ^a  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABIS; ENDOCANNABINOID;

ADIPOSE TISSUE; ALCOHOL CONSUMPTION; BODY MASS; EDITORIAL; FATTY ACID OXIDATION; FATTY LIVER; HEPATITIS C VIRUS; HUMAN; LIPID STORAGE; LIVER DISEASE; NONHUMAN; OBESITY; PRIORITY JOURNAL; SMOKING; STELLATE CELL;

EID: 38649116306     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2007.12.017     Document Type: Editorial

References (30)

1. Pacher P., Bátkai S., and Kunos G. The endocannabinoid system as an emerging target for pharmacotherapy. Pharmacol Rev 58 (2006) 389-462
2. Bátkai S., Járai Z., Wagner J.A., et al. Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med 7 (2001) 827-832
3. Bátkai S., Mukhopadhyay P., Harvey-White J., et al. Endocannabinoids acting at CB1 receptors mediate the cardiac contractile dysfunction in vivo in cirrhotic rats. Am J Physiol Heart Circ Physiol 293 (2007) H1689-H1695
4. Gaskari S.A., Liu H., Moezi L., et al. Role of endocannabinoids in the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats. Br J Pharmacol 146 (2005) 315-323
5. Ros J., Clària J., To-Figueras J., et al. Endogenous cannabinoids: a new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat. Gastroenterology 122 (2002) 85-93
6. Julien B., Grenard P., Teixeira-Clerc F., et al. Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology 128 (2005) 742-755
7. Teixeira-Clerc F., Julien B., Grenard P., et al. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat Med 12 (2006) 672-676
8. Gary-Bobo M., Elachouri G., et al. Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology 46 (2007) 122-129
9. Osei-Hyiaman D., DePetrillo M., Pacher P., et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 115 (2005) 1298-1305
10. Jeong W.I., Osei-Hyiaman D., Park O., et al. Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver. Cell Metab 7 (2008) (in press)
11. Hézode C., Roudot-Thoraval F., Nguyen S., et al. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology 42 (2005) 63-71
12. Hézode C., Zafrani E.S., Roudot-Thoraval F., et al. Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C. Gastroenterology 134 (2008) 432-439
13. Ravinet Trillou C., Delgorge C., Menet C., et al. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord 28 (2004) 640-648
14. Després J.P., Golay A., Sjöström L., and Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353 (2005) 2121-2134
15. Pi-Sunyer F.X., Aronne L.J., Heshmati H.M., et al., RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295 (2006) 761-775
16. Van Gaal L.F., Rissanen A.M., Scheen A.J., et al., RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365 (2005) 1389-1397
17. Bermúdez-Siva F.J., Serrano A., Diaz-Molina F.J., et al. Activation of cannabinoid CB1 receptors induces glucose intolerance in rats. Eur J Pharmacol 531 (2006) 282-284
18. Liu Y.L., Connoley I.P., Wilson C.A., et al. Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. Int J Obes (Lond) 29 (2005) 183-187
19. Poirier B., Bidouard J.P., Cadrouvele C., et al. The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. Diabetes Obes Metab 7 (2005) 65-72
20. Ravinet Trillou C., Arnone M., Delgorge C., et al. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 284 (2003) R345-R353
21. Scheen A.J., Finer N., Hollander P., et al., RIO-Diabetes Study Group. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 368 (2006) 1660-1672
22. Cunnane S.C. Hepatic triacylglycerol accumulation induced by ethanol and carbon tetrachloride: interactions with essential fatty acids and prostaglandins. Alc Clin Exp Res 11 (1987) 25-30
23. Castera L., Chouteau P., Hézode C., et al. Hepatitis C virus-induced hepatocellular steatosis. Am J Gastroenterol 100 (2005) 711-715
24. Adachi Y., Bradford B., Gao W., et al. Inactivation of Kupffer cells prevents early alcohol-induced liver injury. Hepatology 20 (1994) 453-460
25. Duffield J.S., Forbes S.J., Constandinou C.M., et al. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest 115 (2005) 56-65
26. Liu J., Batkai S., Pacher P., et al. Lipopolysaccharide induces anandamide synthesis in macrophages via CD14/MAPK/phosphoinositide 3-kinase/NF-kappaB independently of platelet-activating factor. J Biol Chem 278 (2003) 45034-45039
27. Gao B., Hong F., and Radaeva S. Host factors and failure of interferon-alpha treatment in hepatitis C virus. Hepatology 39 (2004) 880-890
28. Westin J., Lagging M., Dhillon A.P., et al., DITTO-HCV Study Group. Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection. J Viral Hepatol 14 (2007) 29-35
29. Sylvestre D.L., Clements B.J., and Malibu Y. Cannabis use improves retention and virological outcomes in patients treated for hepatitis C. Eur J Gastroenterol Hepatol 18 (2006) 1057-1063
30. Siegmund S.V., Qian T., de Minicis S., et al. The endocannabinoid 2-arachidonoyl glycerol induces death of hepatic stellate cells via mitochondrial reactive oxygen species. FASEB J 21 (2007) 2798-2806